Millrace Asset Group Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tandem Diabetes Care
TNDM
|
+$2.54M |
| 2 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
+$2.54M |
| 3 |
Extreme Networks
EXTR
|
+$2.02M |
| 4 |
DocGo
DCGO
|
+$2.01M |
| 5 |
Azenta
AZTA
|
+$1.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Castle Biosciences
CSTL
|
+$1.65M |
| 2 |
Identive
INVE
|
+$1.56M |
| 3 |
AtriCure
ATRC
|
+$1.45M |
| 4 |
LFG
Archaea Energy Inc.
LFG
|
+$1.4M |
| 5 |
Babcock & Wilcox
BW
|
+$1.39M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 42.27% |
| 2 | Healthcare | 22.85% |
| 3 | Consumer Discretionary | 11.4% |
| 4 | Industrials | 11.09% |
| 5 | Consumer Staples | 7.27% |
Similar funds
Millrace Asset Group's Q4 2022 Portfolio in Review
As of Q4 2022, Millrace Asset Group held 66 positions worth $88.1M, up 11% from $79.2M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Millrace Asset Group deployed $2.94M of net new capital in Q4 2022, opening 14 new positions and adding to 20 existing holdings. Its largest new stake was Tandem Diabetes Care: 56,211 shares worth $2.53M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 42% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was Champions Oncology, an estimated $999K trimmed.
- Millrace Asset Group's largest Q4 2022 buy was Tandem Diabetes Care: 56,211 shares worth $2.53M.
- Millrace Asset Group added most to AXT Inc in Q4 2022, an estimated $1.43M increase.
- Millrace Asset Group's biggest Q4 2022 reduction was Champions Oncology, cutting an estimated $999K.
- Millrace Asset Group fully exited Castle Biosciences in Q4 2022, selling an estimated $1.65M.
- Millrace Asset Group's ten largest holdings make up 40% of its $88.1M portfolio in Q4 2022.
- Millrace Asset Group opened 14 new positions and closed 18 in Q4 2022.
- Millrace Asset Group's portfolio value rose 11% quarter-over-quarter to $88.1M.
Based on Millrace Asset Group's 13F filing for Q4 2022, filed 13 Feb 2023.